Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Core Viewpoint - Ernexa Therapeutics has regained compliance with Nasdaq for continued listing, allowing its stock to continue trading on the Nasdaq Stock Market [1][2]. Company Overview - Ernexa Therapeutics is focused on developing innovative stem cell therapies for advanced cancer and autoimmune diseases, utilizing engineered induced pluripotent stem cells (iPSCs) to create allogeneic synthetic induced mesenchymal stem cells (iMSCs) [4]. - The company’s lead product, ERNA-101, aims to activate and regulate the immune system to target cancer cells, while ERNA-102 is designed to address inflammation in autoimmune diseases [5]. Future Plans - The company is on track to initiate its first clinical trial in early 2026, emphasizing its commitment to advancing its programs for patients with ovarian cancer and autoimmune diseases [3].